The GLP Family: Three Pathways, One Precursor
GLP-1 and GLP-2 are both derived from proglucagon — the same precursor peptide — through tissue-specific proteolytic processing in intestinal L-cells. GLP-3 is a research designation for Retatrutide's multi-receptor profile, not a distinct endogenous peptide.
Despite sharing a precursor, GLP-1 and GLP-2 have entirely different receptor targets, expression patterns, and physiological functions.
GLP-1: The Metabolic Regulator
Receptor: GLP-1R Primary expression: Pancreatic beta cells, CNS (hypothalamus, brainstem), stomach, lung Key effects: Insulin secretion (glucose-dependent), glucagon suppression, gastric emptying delay, CNS appetite suppression
GLP-1 is released from L-cells in response to nutrient ingestion. Its insulin-stimulating effect is "glucose-dependent" — it only triggers insulin release when blood glucose is elevated, which limits hypoglycemia risk.
The CNS effects of GLP-1R activation are equally important: GLP-1R in the hypothalamic arcuate nucleus and brainstem NTS reduces food intake and increases satiety signaling.
Research compound: GLP-1 S (Semaglutide) — a 94% homologous analog with C18 diacid modification for albumin binding (~7-day half-life).
GLP-2: The Intestinal Trophic Factor
Receptor: GLP-2R Primary expression: Intestinal enteroendocrine cells (submucosal neurons, crypt cells) Key effects: Intestinal epithelial proliferation, mucosal surface area expansion, reduced intestinal permeability, enhanced nutrient absorption
GLP-2 has no meaningful metabolic or CNS effects at physiological concentrations — it is almost exclusively an intestinal trophic factor. GLP-2R activation drives crypt cell proliferation (increasing villus height) and inhibits enterocyte apoptosis (reducing cell loss).
The result: expanded intestinal surface area, improved mucosal barrier integrity, and enhanced nutrient absorption capacity.
Research compound: GLP-2 T (Teduglutide) — an analog with Ala²→Gly² substitution conferring DPP-IV resistance and ~2× half-life extension vs native GLP-2.
GLP-3 R: The Triple Agonist
Receptors: GLP-1R + GIPR + Glucagon receptor Research compound: Retatrutide (2381089-83-2)
Retatrutide is not a "GLP-3" in any endocrine biology sense — no endogenous GLP-3 exists. The "GLP-3 R" designation reflects its triple-receptor target profile in research shorthand.
The three-receptor mechanism works through synergistic pathway engagement: - GLP-1R: Appetite suppression + glucose-dependent insulin secretion - GIPR: Additional insulin secretion potentiation, possible GLP-1 nausea attenuation - GcgR: Energy expenditure increase through hepatic glucose modulation and thermogenic pathway activation
The GcgR component is the key differentiator from tirzepatide (GLP-1R + GIPR only). Phase 2 data attributed approximately 6–8% additional weight effect to the glucagon axis above tirzepatide's dual-receptor baseline.
Comparative Research Outcomes
| Compound | Receptors | Peak Phase 2/3 Effect | Trial Duration |
|---|---|---|---|
| GLP-1 S (Semaglutide) | GLP-1R | −14.9% | 68 weeks |
| GLP-2 T (Teduglutide) | GLP-2R | Mucosal (not weight) | 24 weeks |
| GLP-3 R (Retatrutide) | GLP-1R+GIPR+GcgR | −28.7% | 48 weeks |
Which Belongs in Which Research Design
Pure metabolic research: GLP-1 S or GLP-3 R — depending on whether mono or tri-receptor mechanism is the study focus.
Intestinal mucosal research: GLP-2 T — the only compound with primary GLP-2R activity.
Comparative receptor research: All three — enabling controlled comparison of mono, dual, and triple receptor engagement effects on common outcome markers.
Full-protocol stack: GLP-3 R as primary compound, GLP-2 T as gut integrity adjunct.